Publications by authors named "Misti Linaberry"

Claim this Profile
D
Deucravacitinib in Plaque Psoriasis After Inadequate Response to Apremilast: Phase 3 POETYK Analysis.
April W Armstrong, Richard B Warren, Howard Sofen, Lynda Spelman, Misti Linaberry

Dermatol Ther (Heidelb)· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasis.
Mark Lebwohl, Melinda J Gooderham, Richard B Warren, Diamant Thaçi, Peter Foley, Misti Linaberry

Clin Exp Dermatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cendakimab in Patients With Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.
Andrew Blauvelt, Emma Guttman-Yassky, Charles Lynde, Saakshi Khattri, Joel Schlessinger, Misti Linaberry

JAMA Dermatol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-1 study): a plain language summary.
April W Armstrong, Melinda Gooderham, Richard B Warren, Kim A Papp, Bruce Strober, Misti Linaberry

Immunotherapy· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary.
Bruce Strober, Diamant Thaçi, Howard Sofen, Leon Kircik, Kenneth B Gordon, Misti Linaberry

Immunotherapy· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
April W Armstrong, Melinda Gooderham, Richard B Warren, Kim A Papp, Bruce Strober, Misti Linaberry

J Am Acad Dermatol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
Bruce Strober, Diamant Thaçi, Howard Sofen, Leon Kircik, Kenneth B Gordon, Misti Linaberry

J Am Acad Dermatol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C).
Fred Poordad, Mitchell L Shiffman, Wayne Ghesquiere, Alexander Wong, Gregory D Huhn, Misti Linaberry

Antivir Ther· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens.
K Rajender Reddy, Stanislas Pol, Paul J Thuluvath, Hiromitsu Kumada, Joji Toyota, Misti Linaberry

Liver Int· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study).
Mark S Sulkowski, Steve Flamm, Zeid Kayali, Eric J Lawitz, Paul Kwo, Misti Linaberry

Liver Int· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection.
Joji Toyota, Yoshiyasu Karino, Fumitaka Suzuki, Fusao Ikeda, Akio Ido, Misti Linaberry

J Gastroenterol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients.
Hiromitsu Kumada, Fumitaka Suzuki, Yoshiyuki Suzuki, Joji Toyota, Yoshiyasu Karino, Misti Linaberry

J Gastroenterol Hepatol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
Michael Manns, Stanislas Pol, Ira M Jacobson, Patrick Marcellin, Stuart C Gordon, Misti Linaberry

Lancet· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes of the Ajust Adjustable Single-Incision Sling for the treatment of stress urinary incontinence.
Gert Naumann, Thomas Hagemeier, Stefan Zachmann, Aktham Al-Ani, Stefan Albrich, Misti Linaberry

Int Urogynecol J· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis